title: BRAFV600E mutation associated with non-radioiodine-avid status in distant metastatic papillary thyroid carcinoma.
abstract: OBJECTIVE
  It was reported that BRAF mutation correlates with radioactive iodine refractory papillary thyroid carcinoma (PTC) in local recurrence, whereas its relationship with I uptake status in distant metastatic PTC remains uncertain. This prospective study tried to explore the association between I uptake in distant metastases (DM) of PTC and BRAF mutation status in their primary tumor.
  
  
  METHODS
  Seventy-three patients with DM were divided into BRAF mutation group (n = 19) and wild-type BRAF group (n = 54) according to the BRAF mutation status. After posttherapy I whole-body scan was performed, the relation between I uptake in DM, BRAF mutation status, and clinicopathological characteristics of 2 groups were compared.
  
  
  RESULTS
  The mean age of mutation group was older than that of the wild-type group (P < 0.05). In the mutation group, 16 patients (84.2%, 16 of 19) were found to be with non-iodine-avid DM, whereas in wild-type group, only 5.6% (3 of 54) were with non-iodine-avid DM. The sensitivity and specificity of using BRAF mutation for the identification of non-iodine-avid DM were 84.2% and 94.4%, respectively.
  
  
  CONCLUSIONS
  BRAF mutation in primary tumor might be a promising molecular marker to predict the status of I uptake in distal metastases.
authors: From the *Department of Nuclear Medicine, Pecking Union Medical College Hospital, Beijing; †Department of Oncology, the Affiliated Hospital of Qingdao University Medical College, Qingdao; and ‡Department of Pathology, Pecking Union Medical College Hospital, Beijing, China.
authors: Ke
authors: K
authors: Yang
authors: Hao
authors: H
authors: Wang
authors: Zhiyong
authors: Z
authors: Liang
authors: Jun
authors: J
authors: Liang
authors: Fang
authors: F
authors: Li
authors: Yansong
authors: Y
authors: Lin
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000235:genetics*; D002277:Carcinoma / Q000000981:diagnostic imaging* / Q000235:genetics / Q000473:pathology; D002291:Carcinoma, Papillary; D016022:Case-Control Studies; D002648:Child; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000493:pharmacokinetics*; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging; D020125:Mutation, Missense; D009362:Neoplasm Metastasis / Q000000981:diagnostic imaging; D049268:Positron-Emission Tomography; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics*; D000077273:Thyroid Cancer, Papillary; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging* / Q000235:genetics / Q000473:pathology; D014057:Tomography, X-Ray Computed
chemical_list: D014408:Biomarkers, Tumor; D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf